SpringerLink
Log in

Alzheimer’s Disease and Frontotemporal Lobar Degeneration: Mouse Models

  • Chapter
  • First Online:
Neurodegenerative Diseases

Abstract

Genetically modified mouse models have been instrumental in deciphering pathomechanisms in a large variety of human conditions. Accordingly, transgenic and knockout mice have contributed to understanding neurodegenerative processes in Alzheimer’s disease (AD) and frontotemporal lobar degeneration (FTLD). While initial models for AD and FTLD based on mutations in APP and tau have been generated more than a decade ago, identification of novel genes involved in disease has markedly increased the spectrum of available FTLD mouse models. This chapter provides an overview of APP and tau-based mouse models of AD and FTLD and how these models have advanced our understanding of disease mechanisms as well as discusses more recent FTLD models of novel disease genes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Brinster RL, Cross PC. Effect of copper on the preimplantation mouse embryo. Nature. 1972;238(5364):398–9.

    Article  CAS  PubMed  Google Scholar 

  2. Ittner LM, Gotz J. Pronuclear injection for the production of transgenic mice. Nat Protoc. 2007;2(5):1206–15.

    Article  CAS  PubMed  Google Scholar 

  3. Delerue F, White M, Ittner LM. Inducible, tightly regulated and non-leaky neuronal gene expression in mice. Transgenic Res. 2014;23(2):225–33.

    Article  CAS  PubMed  Google Scholar 

  4. Geurts AM, Cost GJ, Freyvert Y, Zeitler B, Miller JC, Choi VM, et al. Knockout rats via embryo microinjection of zinc-finger nucleases. Science. 2009;325(5939):433.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Sung YH, Baek IJ, Kim DH, Jeon J, Lee J, Lee K, et al. Knockout mice created by TALEN-mediated gene targeting. Nat Biotechnol. 2013;31(1):23–4.

    Article  CAS  PubMed  Google Scholar 

  6. Delerue F, Ittner LM. Genome editing in mice using CRISPR/Cas9: achievements and prospects. Clon Transgen. 2015;4:2.

    Google Scholar 

  7. Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell. 2013;153(4):910–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Yang H, Wang H, Shivalila CS, Cheng AW, Shi L, Jaenisch R. One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell. 2013;154(6):1370–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kleinberger G, Brendel M, Mracsko E, Wefers B, Groeneweg L, **ang X, et al. The FTD-like syndrome causing TREM2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism. EMBO J. 2017;36(13):1837–53.

    Article  CAS  PubMed  Google Scholar 

  10. Gotz J, Ittner LM. Animal models of Alzheimer’s disease and frontotemporal dementia. Nat Rev Neurosci. 2008;9(7):532–44.

    Article  PubMed  CAS  Google Scholar 

  11. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995;373(6514):523–7.

    Article  CAS  PubMed  Google Scholar 

  12. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science. 2006;313(5794):1781–4.

    Article  CAS  PubMed  Google Scholar 

  13. Verret L, Mann EO, Hang GB, Barth AM, Cobos I, Ho K, et al. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell. 2012;149(3):708–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Ittner AA, Gladbach A, Bertz J, Suh LS, Ittner LM. p38 MAP kinase-mediated NMDA receptor-dependent suppression of hippocampal hypersynchronicity in a mouse model of Alzheimer inverted question marks disease. Acta Neuropathol Commun. 2014;2(1):149.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Lam AD, Deck G, Goldman A, Eskandar EN, Noebels J, Cole AJ. Silent hippocampal seizures and spikes identified by foramen ovale electrodes in Alzheimer’s disease. Nat Med. 2017;23(6):678–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C, et al. Neuron loss in APP transgenic mice. Nature. 1998;395(6704):755–6.

    Article  CAS  PubMed  Google Scholar 

  17. Wright AL, Zinn R, Hohensinn B, Konen LM, Beynon SB, Tan RP, et al. Neuroinflammation and neuronal loss precede Abeta plaque deposition in the hAPP-J20 mouse model of Alzheimer’s disease. PLoS One. 2013;8(4):e59586.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Guo Q, Wang Z, Li H, Wiese M, Zheng H. APP physiological and pathophysiological functions: insights from animal models. Cell Res. 2012;22(1):78–89.

    Article  CAS  PubMed  Google Scholar 

  19. Wang P, Yang G, Mosier DR, Chang P, Zaidi T, Gong YD, et al. Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-Like protein 2. J Neurosci. 2005;25(5):1219–25.

    Article  CAS  PubMed  Google Scholar 

  20. Zheng H, Jiang M, Trumbauer ME, Sirinathsinghji DJ, Hopkins R, Smith DW, et al. beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell. 1995;81(4):525–31.

    Article  CAS  PubMed  Google Scholar 

  21. Li ZW, Stark G, Gotz J, Rulicke T, Gschwind M, Huber G, et al. Generation of mice with a 200-kb amyloid precursor protein gene deletion by Cre recombinase-mediated site-specific recombination in embryonic stem cells. Proc Natl Acad Sci U S A. 1996;93(12):6158–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Duce JA, Tsatsanis A, Cater MA, James SA, Robb E, Wikhe K, et al. Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer’s disease. Cell. 2010;142(6):857–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, et al. Single App knock-in mouse models of Alzheimer’s disease. Nat Neurosci. 2014;17(5):661–3.

    Article  CAS  PubMed  Google Scholar 

  24. Saito T, Matsuba Y, Yamazaki N, Hashimoto S, Saido TC. Calpain activation in Alzheimer’s model mice is an artifact of APP and presenilin overexpression. J Neurosci. 2016;36(38):9933–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Masuda A, Kobayashi Y, Kogo N, Saito T, Saido TC, Itohara S. Cognitive deficits in single App knock-in mouse models. Neurobiol Learn Mem. 2016;135:73–82.

    Article  CAS  PubMed  Google Scholar 

  26. Ittner A, Chua SW, Bertz J, Volkerling A, van der Hoven J, Gladbach A, et al. Site-specific phosphorylation of tau inhibits amyloid-beta toxicity in Alzheimer’s mice. Science. 2016;354(6314):904–8.

    Article  CAS  PubMed  Google Scholar 

  27. Chin J, Palop JJ, GQ Y, Kojima N, Masliah E, Mucke L. Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neurosci. 2004;24(19):4692–7.

    Article  CAS  PubMed  Google Scholar 

  28. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell. 2010;142(3):387–97.

    Article  CAS  PubMed  Google Scholar 

  29. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 1998;4(1):97–100.

    Article  CAS  PubMed  Google Scholar 

  30. Schmitz C, Rutten BP, Pielen A, Schafer S, Wirths O, Tremp G, et al. Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer’s disease. Am J Pathol. 2004;164(4):1495–502.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Wang R, Wang B, He W, Zheng H. Wild-type presenilin 1 protects against Alzheimer disease mutation-induced amyloid pathology. J Biol Chem. 2006;281(22):15330–6.

    Article  CAS  PubMed  Google Scholar 

  32. Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, et al. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer’s disease. Neuron. 2004;41(1):27–33.

    Article  CAS  PubMed  Google Scholar 

  33. McConlogue L, Buttini M, Anderson JP, Brigham EF, Chen KS, Freedman SB, et al. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. J Biol Chem. 2007;282(36):26326–34.

    Article  CAS  PubMed  Google Scholar 

  34. Ma H, Lesne S, Kotilinek L, Steidl-Nichols JV, Sherman M, Younkin L, et al. Involvement of beta-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity. Proc Natl Acad Sci U S A. 2007;104(19):8167–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Willem M, Dewachter I, Smyth N, Van Dooren T, Borghgraef P, Haass C, et al. beta-site amyloid precursor protein cleaving enzyme 1 increases amyloid deposition in brain parenchyma but reduces cerebrovascular amyloid angiopathy in aging BACE x APP[V717I] double-transgenic mice. Am J Pathol. 2004;165(5):1621–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. J Clin Invest. 2005;115(6):1449–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet. 1997;17(3):263–4.

    Article  CAS  PubMed  Google Scholar 

  38. Dodart JC, Marr RA, Koistinaho M, Gregersen BM, Malkani S, Verma IM, et al. Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2005;102(4):1211–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293(5534):1487–91.

    Article  CAS  PubMed  Google Scholar 

  40. Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2001;293(5534):1491–5.

    Article  CAS  PubMed  Google Scholar 

  41. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model. Science. 2007;316(5825):750–4.

    Article  CAS  PubMed  Google Scholar 

  42. Ittner LM, Gotz J. Amyloid-beta and tau—a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci. 2011;12(2):67–72.

    Article  CAS  Google Scholar 

  43. Mondragon-Rodriguez S, Trillaud-Doppia E, Dudilot A, Bourgeois C, Lauzon M, Leclerc N, et al. Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation. J Biol Chem. 2012;287(38):32040–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Nakanishi N, Ryan SD, Zhang X, Khan A, Holland T, Cho EG, et al. Synaptic protein alpha1-Takusan mitigates amyloid-beta-induced synaptic loss via interaction with tau and postsynaptic density-95 at postsynaptic sites. J Neurosci. 2013;33(35):14170–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. DeVos SL, Hyman BT. Tau at the crossroads between neurotoxicity and neuroprotection. Neuron. 2017;94(4):703–4.

    Article  CAS  PubMed  Google Scholar 

  46. Vanden Dries V, Stygelbout V, Pierrot N, Yilmaz Z, Suain V, De Decker R, et al. Amyloid precursor protein reduction enhances the formation of neurofibrillary tangles in a mutant tau transgenic mouse model. Neurobiol Aging. 2017;55:202–12.

    Article  CAS  Google Scholar 

  47. Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer’s disease. Ann Neurol. 2007;61(5):435–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Uryu K, Nakashima-Yasuda H, Forman MS, Kwong LK, Clark CM, Grossman M, et al. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol. 2008;67(6):555–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Arai T, Mackenzie IR, Hasegawa M, Nonoka T, Niizato K, Tsuchiya K, et al. Phosphorylated TDP-43 in Alzheimer’s disease and dementia with Lewy bodies. Acta Neuropathol. 2009;117(2):125–36.

    Article  CAS  PubMed  Google Scholar 

  50. LaClair KD, Donde A, Ling JP, Jeong YH, Chhabra R, Martin LJ, et al. Depletion of TDP-43 decreases fibril and plaque beta-amyloid and exacerbates neurodegeneration in an Alzheimer’s mouse model. Acta Neuropathol. 2016;132(6):859–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Davis SA, Gan KA, Dowell JA, Cairns NJ, Gitcho MA. TDP-43 expression influences amyloidbeta plaque deposition and tau aggregation. Neurobiol Dis. 2017;103:154–62.

    Article  CAS  PubMed  Google Scholar 

  52. Paolicelli RC, Jawaid A, Henstridge CM, Valeri A, Merlini M, Robinson JL, et al. TDP-43 depletion in microglia promotes amyloid clearance but also induces synapse loss. Neuron. 2017;95(2):297–308 e6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Josephs KA, Whitwell JL, Weigand SD, Murray ME, Tosakulwong N, Liesinger AM, et al. TDP-43 is a key player in the clinical features associated with Alzheimer’s disease. Acta Neuropathol. 2014;127(6):811–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Mackenzie IR, Munoz DG, Kusaka H, Yokota O, Ishihara K, Roeber S, et al. Distinct pathological subtypes of FTLD-FUS. Acta Neuropathol. 2011;121(2):207–18.

    Article  PubMed  Google Scholar 

  55. Burrell JR, Halliday GM, Kril JJ, Ittner LM, Gotz J, Kiernan MC, et al. The frontotemporal dementia-motor neuron disease continuum. Lancet. 2016;388(10047):919–31.

    Article  PubMed  Google Scholar 

  56. Ittner LM, Halliday GM, Kril JJ, Gotz J, Hodges JR, Kiernan MCFTD. ALS-translating mouse studies into clinical trials. Nat Rev Neurol. 2015;11(6):360–6.

    Article  PubMed  Google Scholar 

  57. Gotz J, Probst A, Spillantini MG, Schafer T, Jakes R, Burki K, et al. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J. 1995;14(7):1304–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25(4):402–5.

    Article  CAS  PubMed  Google Scholar 

  59. Dawson HN, Cantillana V, Chen L, Vitek MP. The tau N279K exon 10 splicing mutation recapitulates frontotemporal dementia and parkinsonism linked to chromosome 17 tauopathy in a mouse model. J Neurosci. 2007;27(34):9155–68.

    Article  CAS  PubMed  Google Scholar 

  60. Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci. 2002;22(21):9340–51.

    CAS  PubMed  Google Scholar 

  61. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53(3):337–51.

    Article  CAS  PubMed  Google Scholar 

  62. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309(5733):476–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Mocanu MM, Nissen A, Eckermann K, Khlistunova I, Biernat J, Drexler D, et al. The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy. J Neurosci. 2008;28(3):737–48.

    Article  CAS  PubMed  Google Scholar 

  64. Forman MS, Lal D, Zhang B, Dabir DV, Swanson E, Lee VM, et al. Transgenic mouse model of tau pathology in astrocytes leading to nervous system degeneration. J Neurosci. 2005;25(14):3539–50.

    Article  CAS  PubMed  Google Scholar 

  65. Higuchi M, Zhang B, Forman MS, Yoshiyama Y, Trojanowski JQ, Lee VM. Axonal degeneration induced by targeted expression of mutant human tau in oligodendrocytes of transgenic mice that model glial tauopathies. J Neurosci. 2005;25(41):9434–43.

    Article  CAS  PubMed  Google Scholar 

  66. van Eersel J, Stevens CH, Przybyla M, Gladbach A, Stefanoska K, Chan CK, et al. Early-onset axonal pathology in a novel P301S-Tau transgenic mouse model of frontotemporal lobar degeneration. Neuropathol Appl Neurobiol. 2015;41(7):906–25.

    Article  PubMed  CAS  Google Scholar 

  67. Przybyla M, Stevens CH, van der Hoven J, Harasta A, Bi M, Ittner A, et al. Disinhibition-like behavior in a P301S mutant tau transgenic mouse model of frontotemporal dementia. Neurosci Lett. 2016;631:24–9.

    Article  CAS  PubMed  Google Scholar 

  68. Van der Jeugd A, Vermaercke B, Halliday GM, Staufenbiel M, Gotz J. Impulsivity, decreased social exploration, and executive dysfunction in a mouse model of frontotemporal dementia. Neurobiol Learn Mem. 2016;130:34–43.

    Article  PubMed  CAS  Google Scholar 

  69. Aguzzi A, Rajendran L. The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron. 2009;64(6):783–90.

    Article  CAS  PubMed  Google Scholar 

  70. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11(7):909–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Clavaguera F, Akatsu H, Fraser G, Crowther RA, Frank S, Hench J, et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A. 2013;110(23):9535–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. 2014;82(6):1271–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Kaufman SK, Sanders DW, Thomas TL, Ruchinskas AJ, Vaquer-Alicea J, Sharma AM, et al. Tau prion strains dictate patterns of cell pathology, progression rate, and regional vulnerability in vivo. Neuron. 2016;92(4):796–812.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Liu L, Drouet V, JW W, Witter MP, Small SA, Clelland C, et al. Trans-synaptic spread of tau pathology in vivo. PLoS One. 2012;7(2):e31302.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Jackson SJ, Kerridge C, Cooper J, Cavallini A, Falcon B, Cella CV, et al. Short fibrils constitute the major species of seed-competent tau in the brains of mice transgenic for human P301S tau. J Neurosci. 2016;36(3):762–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Kim D, Lim S, Haque MM, Ryoo N, Hong HS, Rhim H, et al. Identification of disulfide cross-linked tau dimer responsible for tau propagation. Sci Rep. 2015;5:15231.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Asai H, Ikezu S, Tsunoda S, Medalla M, Luebke J, Haydar T, et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci. 2015;18(11):1584–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Baker S, Polanco JC, Gotz J. Extracellular vesicles containing P301L mutant tau accelerate pathological tau phosphorylation and oligomer formation but do not seed mature neurofibrillary tangles in ALZ17 mice. J Alzheimers Dis. 2016;54(3):1207–17.

    Article  CAS  PubMed  Google Scholar 

  79. Yamada K, Holth JK, Liao F, Stewart FR, Mahan TE, Jiang H, et al. Neuronal activity regulates extracellular tau in vivo. J Exp Med. 2014;211(3):387–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. JW W, Hussaini SA, Bastille IM, Rodriguez GA, Mrejeru A, Rilett K, et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat Neurosci. 2016;19(8):1085–92.

    Article  CAS  Google Scholar 

  81. Wegmann S, Maury EA, Kirk MJ, Saqran L, Roe A, DeVos SL, et al. Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity. EMBO J. 2015;34(24):3028–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. DeVos SL, Miller RL, Schoch KM, Holmes BB, Kebodeaux CS, Wegener AJ, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med. 2017;9(374):eaag0481.

    Google Scholar 

  83. Holth JK, Mahan TE, Robinson GO, Rocha A, Holtzman DM. Altered sleep and EEG power in the P301S Tau transgenic mouse model. Ann Clin Transl Neurol. 2017;4(3):180–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Maeda S, Djukic B, Taneja P, GQ Y, Lo I, Davis A, et al. Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice. EMBO Rep. 2016;17(4):530–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Koss DJ, Robinson L, Drever BD, Plucinska K, Stoppelkamp S, Veselcic P, et al. Mutant Tau knock-in mice display frontotemporal dementia relevant behaviour and histopathology. Neurobiol Dis. 2016;91:105–23.

    Article  CAS  PubMed  Google Scholar 

  86. Kim Y, Choi H, Lee W, Park H, Kam TI, Hong SH, et al. Caspase-cleaved tau exhibits rapid memory impairment associated with tau oligomers in a transgenic mouse model. Neurobiol Dis. 2016;87:19–28.

    Article  CAS  PubMed  Google Scholar 

  87. Zhao X, Kotilinek LA, Smith B, Hlynialuk C, Zahs K, Ramsden M, et al. Caspase-2 cleavage of tau reversibly impairs memory. Nat Med. 2016;22(11):1268–76.

    Article  CAS  PubMed  Google Scholar 

  88. Bondulich MK, Guo T, Meehan C, Manion J, Rodriguez Martin T, Mitchell JC, et al. Tauopathy induced by low level expression of a human brain-derived tau fragment in mice is rescued by phenylbutyrate. Brain. 2016;139(Pt 8):2290–306.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Min SW, Chen X, Tracy TE, Li Y, Zhou Y, Wang C, et al. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med. 2015;21(10):1154–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci. 2007;27(34):9115–29.

    Article  CAS  PubMed  Google Scholar 

  91. Bi M, Ittner A, Ke YD, Gotz J, Ittner LM. Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One. 2011;6(12):e26860.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol. 2010;224(2):472–85.

    Article  CAS  PubMed  Google Scholar 

  93. Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, et al. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem. 2011;286(39):34457–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Yanamandra K, Patel TK, Jiang H, Schindler S, Ulrich JD, Boxer AL, et al. Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. Sci Transl Med. 2017;9(386):eaal2029.

    Google Scholar 

  95. Ising C, Gallardo G, Leyns CEG, Wong CH, Stewart F, Koscal LJ, et al. AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy. J Exp Med. 2017;214(5):1227–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Lee SH, Le Pichon CE, Adolfsson O, Gafner V, Pihlgren M, Lin H, et al. Antibody-mediated targeting of Tau in vivo does not require effector function and microglial engagement. Cell Rep. 2016;16(6):1690–700.

    Article  CAS  PubMed  Google Scholar 

  97. Nisbet RM, Van der Jeugd A, Leinenga G, Evans HT, Janowicz PW, Gotz J. Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model. Brain. 2017;140(5):1220–30.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Davtyan H, Chen WW, Zagorski K, Davis J, Petrushina I, Kazarian K, et al. MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice. Vaccine. 2017;35(16):2015–24.

    Article  CAS  PubMed  Google Scholar 

  99. van Eersel J, Ke YD, Liu X, Delerue F, Kril JJ, Gotz J, et al. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer’s disease models. Proc Natl Acad Sci U S A. 2010;107(31):13888–93.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Brunden KR, Zhang B, Carroll J, Yao Y, Potuzak JS, Hogan AM, et al. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neurosci. 2010;30(41):13861–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Yu L, Wang W, Pang W, **ao Z, Jiang Y, Hong Y. Dietary lycopene supplementation improves cognitive performances in tau transgenic mice expressing P301L mutation via inhibiting oxidative stress and tau hyperphosphorylation. J Alzheimers Dis. 2017;57(2):475–82.

    Article  CAS  PubMed  Google Scholar 

  102. Chua SW, Cornejo A, van Eersel J, Stevens CH, Vaca I, Cueto M, et al. The polyphenol altenusin inhibits in vitro fibrillization of tau and reduces induced tau pathology in primary neurons. ACS Chem Nerosci. 2017;8(4):743–51.

    Article  CAS  Google Scholar 

  103. Makani V, Zhang B, Han H, Yao Y, Lassalas P, Lou K, et al. Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy. Acta Neuropathol Commun. 2016;4(1):106.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  104. Dennissen FJ, Anglada-Huguet M, Sydow A, Mandelkow E, Mandelkow EM. Adenosine A1 receptor antagonist rolofylline alleviates axonopathy caused by human Tau DeltaK280. Proc Natl Acad Sci U S A. 2016;113(41):11597–602.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Wagner J, Krauss S, Shi S, Ryazanov S, Steffen J, Miklitz C, et al. Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Acta Neuropathol. 2015;130(5):619–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Qin Y, Liu Y, Hao W, Decker Y, Tomic I, Menger MD, et al. Stimulation of TLR4 attenuates Alzheimer’s disease-related symptoms and pathology in tau-transgenic mice. J Immunol. 2016;197(8):3281–92.

    Article  CAS  PubMed  Google Scholar 

  107. Hansen HH, Barkholt P, Fabricius K, Jelsing J, Terwel D, Pyke C, et al. The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy. Brain Res. 2016;1634:158–70.

    Article  CAS  PubMed  Google Scholar 

  108. Myeku N, Clelland CL, Emrani S, Kukushkin NV, Yu WH, Goldberg AL, et al. Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nat Med. 2016;22(1):46–53.

    Article  CAS  PubMed  Google Scholar 

  109. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130–3.

    Article  CAS  PubMed  Google Scholar 

  110. Buratti E, Baralle FE. Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. Front Biosci. 2008;13:867–78.

    Article  CAS  PubMed  Google Scholar 

  111. Liscic RM, Grinberg LT, Zidar J, Gitcho MA, Cairns NJ. ALS and FTLD: two faces of TDP-43 proteinopathy. Eur J Neurol. 2008;15(8):772–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A. 2009;106(44):18809–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Guo Y, Wang Q, Zhang K, An T, Shi P, Li Z, et al. HO-1 induction in motor cortex and intestinal dysfunction in TDP-43 A315T transgenic mice. Brain Res. 2012;1460:88–95.

    Article  CAS  PubMed  Google Scholar 

  114. Esmaeili MA, Panahi M, Yadav S, Hennings L, Kiaei M. Premature death of TDP-43 (A315T) transgenic mice due to gastrointestinal complications prior to development of full neurological symptoms of amyotrophic lateral sclerosis. Int J Exp Pathol. 2013;94(1):56–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Hatzipetros T, Bogdanik LP, Tassinari VR, Kidd JD, Moreno AJ, Davis C, et al. C57BL/6J congenic Prp-TDP43A315T mice develop progressive neurodegeneration in the myenteric plexus of the colon without exhibiting key features of ALS. Brain Res. 2014;1584:59–72.

    Article  CAS  PubMed  Google Scholar 

  116. Herdewyn S, Cirillo C, Van Den Bosch L, Robberecht W, Vanden Berghe P, Van Damme P. Prevention of intestinal obstruction reveals progressive neurodegeneration in mutant TDP-43 (A315T) mice. Mol Neurodegener. 2014;9:24.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  117. Wils H, Kleinberger G, Janssens J, Pereson S, Joris G, Cuijt I, et al. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A. 2010;107(8):3858–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. YF X, Gendron TF, Zhang YJ, Lin WL, D’Alton S, Sheng H, et al. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J Neurosci. 2010;30(32):10851–9.

    Article  CAS  Google Scholar 

  119. Igaz LM, Kwong LK, Lee EB, Chen-Plotkin A, Swanson E, Unger T, et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J Clin Invest. 2011;121(2):726–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Stallings NR, Puttaparthi K, Luther CM, Burns DK, Elliott JL. Progressive motor weakness in transgenic mice expressing human TDP-43. Neurobiol Dis. 2010;40(2):404–14.

    Article  CAS  PubMed  Google Scholar 

  121. Swarup V, Phaneuf D, Bareil C, Robertson J, Rouleau GA, Kriz J, et al. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain. 2011;134(Pt 9):2610–26.

    Article  PubMed  Google Scholar 

  122. Ke YD, van Hummel A, Stevens CH, Gladbach A, Ippati S, Bi M, et al. Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS. Acta Neuropathol. 2015;130(5):661–78.

    Article  CAS  PubMed  Google Scholar 

  123. Walker AK, Spiller KJ, Ge G, Zheng A, Xu Y, Zhou M, et al. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. Acta Neuropathol. 2015;130(5):643–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Spiller KJ, Cheung CJ, Restrepo CR, Kwong LK, Stieber AM, Trojanowski JQ, et al. Selective motor neuron resistance and recovery in a new inducible mouse model of TDP-43 proteinopathy. J Neurosci. 2016;36(29):7707–17.

    Article  CAS  PubMed  Google Scholar 

  125. Winton MJ, Igaz LM, Wong MM, Kwong LK, Trojanowski JQ, Lee VM. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J Biol Chem. 2008;283(19):13302–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Alfieri JA, Pino NS, Igaz LM. Reversible behavioral phenotypes in a conditional mouse model of TDP-43 proteinopathies. J Neurosci. 2014;34(46):15244–59.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  127. Alfieri JA, Silva PR, Igaz LM. Early cognitive/social deficits and late motor phenotype in conditional wild-type TDP-43 transgenic mice. Front Aging Neurosci. 2016;8:310.

    Article  PubMed  PubMed Central  Google Scholar 

  128. Cannon A, Yang B, Knight J, Farnham IM, Zhang Y, Wuertzer CA, et al. Neuronal sensitivity to TDP-43 overexpression is dependent on timing of induction. Acta Neuropathol. 2012;123(6):807–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. D’Alton S, Altshuler M, Cannon A, Dickson DW, Petrucelli L, Lewis J. Divergent phenotypes in mutant TDP-43 transgenic mice highlight potential confounds in TDP-43 transgenic modeling. PLoS One. 2014;9(1):e86513.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  130. Zhang W, Zhang L, Liang B, Schroeder D, Zhang ZW, Cox GA, et al. Hyperactive somatostatin interneurons contribute to excitotoxicity in neurodegenerative disorders. Nat Neurosci. 2016;19(4):557–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Handley EE, Pitman KA, Dawkins E, Young KM, Clark RM, Jiang TC, et al. Synapse dysfunction of layer V pyramidal neurons precedes neurodegeneration in a mouse model of TDP-43 proteinopathies. Cereb Cortex. 2017;27(7):3630–47.

    PubMed  Google Scholar 

  132. Wang W, Wang L, Lu J, Siedlak SL, Fujioka H, Liang J, et al. The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. Nat Med. 2016;22(8):869–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Wang W, Arakawa H, Wang L, Okolo O, Siedlak SL, Jiang Y, et al. Motor-coordinative and cognitive dysfunction caused by mutant TDP-43 could be reversed by inhibiting its mitochondrial localization. Mol Ther. 2017;25(1):127–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Wenqiang C, Lonskaya I, Hebron ML, Ibrahim Z, Olszewski RT, Neale JH, et al. Parkin-mediated reduction of nuclear and soluble TDP-43 reverses behavioral decline in symptomatic mice. Hum Mol Genet. 2014;23(18):4960–9.

    Article  CAS  PubMed  Google Scholar 

  135. Heyburn L, Hebron ML, Smith J, Winston C, Bechara J, Li Z, et al. Tyrosine kinase inhibition reverses TDP-43 effects on synaptic protein expression, astrocytic function and amino acid dis-homeostasis. J Neurochem. 2016;139(4):610–23.

    Article  CAS  PubMed  Google Scholar 

  136. Kawamata H, Peixoto P, Konrad C, Palomo G, Bredvik K, Gerges M, et al. Mutant TDP-43 does not impair mitochondrial bioenergetics in vitro and in vivo. Mol Neurodegener. 2017;12(1):37.

    Article  PubMed  PubMed Central  Google Scholar 

  137. Caccamo A, Majumder S, Oddo S. Cognitive decline typical of frontotemporal lobar degeneration in transgenic mice expressing the 25-kDa C-terminal fragment of TDP-43. Am J Pathol. 2012;180(1):293–302.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Caccamo A, Shaw DM, Guarino F, Messina A, Walker AW, Oddo S. Reduced protein turnover mediates functional deficits in transgenic mice expressing the 25 kDa C-terminal fragment of TDP-43. Hum Mol Genet. 2015;24(16):4625–35.

    Article  CAS  PubMed  Google Scholar 

  139. Walker AK, Tripathy K, Restrepo CR, Ge G, Xu Y, Kwong LK, et al. An insoluble frontotemporal lobar degeneration-associated TDP-43 C-terminal fragment causes neurodegeneration and hippocampus pathology in transgenic mice. Hum Mol Genet. 2015;24(25):7241–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  140. Mitchell JC, Constable R, So E, Vance C, Scotter E, Glover L, et al. Wild type human TDP-43 potentiates ALS-linked mutant TDP-43 driven progressive motor and cortical neuron degeneration with pathological features of ALS. Acta Neuropathol Commun. 2015;3:36.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  141. Correia AS, Patel P, Dutta K, Julien JP. Inflammation induces TDP-43 mislocalization and aggregation. PLoS One. 2015;10(10):e0140248.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  142. Iguchi Y, Eid L, Parent M, Soucy G, Bareil C, Riku Y, et al. Exosome secretion is a key pathway for clearance of pathological TDP-43. Brain. 2016;139(Pt 12):3187–201.

    Article  PubMed  Google Scholar 

  143. Clip**er AK, D’Alton S, Lin WL, Gendron TF, Howard J, Borchelt DR, et al. Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy. Acta Neuropathol. 2013;126(1):39–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  144. Gu J, Wu F, Xu W, Shi J, Hu W, ** N, et al. TDP-43 suppresses tau expression via promoting its mRNA instability. Nucleic Acids Res. 2017;45(10):6177–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  145. Kraemer BC, Schuck T, Wheeler JM, Robinson LC, Trojanowski JQ, Lee VM, et al. Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol. 2010;119(4):409–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Becker LA, Huang B, Bieri G, Ma R, Knowles DA, Jafar-Nejad P, et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544(7650):367–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  147. Perera ND, Sheean RK, Crouch PJ, White AR, Horne MK, Turner BJ. Enhancing survival motor neuron expression extends lifespan and attenuates neurodegeneration in mutant TDP-43 mice. Hum Mol Genet. 2016;25(18):4080–93.

    Article  CAS  PubMed  Google Scholar 

  148. Dutta K, Patel P, Rahimian R, Phaneuf D, Julien JP. Withania somnifera reverses transactive response DNA binding protein 43 proteinopathy in a mouse model of amyotrophic lateral sclerosis/frontotemporal lobar degeneration. Neurotherapeutics. 2017;14(2):447–62.

    Article  CAS  PubMed  Google Scholar 

  149. Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442(7105):916–9.

    Article  CAS  PubMed  Google Scholar 

  150. Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature. 2006;442(7105):920–4.

    Article  CAS  PubMed  Google Scholar 

  151. Shankaran SS, Capell A, Hruscha AT, Fellerer K, Neumann M, Schmid B, et al. Missense mutations in the progranulin gene linked to frontotemporal lobar degeneration with ubiquitin-immunoreactive inclusions reduce progranulin production and secretion. J Biol Chem. 2008;283(3):1744–53.

    Article  CAS  PubMed  Google Scholar 

  152. Wang J, Van Damme P, Cruchaga C, Gitcho MA, Vidal JM, Seijo-Martinez M, et al. Pathogenic cysteine mutations affect progranulin function and production of mature granulins. J Neurochem. 2010;112(5):1305–15.

    Article  CAS  PubMed  Google Scholar 

  153. Kayasuga Y, Chiba S, Suzuki M, Kikusui T, Matsuwaki T, Yamanouchi K, et al. Alteration of behavioural phenotype in mice by targeted disruption of the progranulin gene. Behav Brain Res. 2007;185(2):110–8.

    Article  CAS  PubMed  Google Scholar 

  154. Yin F, Banerjee R, Thomas B, Zhou P, Qian L, Jia T, et al. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med. 2010;207(1):117–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  155. Petkau TL, Neal SJ, Milnerwood A, Mew A, Hill AM, Orban P, et al. Synaptic dysfunction in progranulin-deficient mice. Neurobiol Dis. 2012;45(2):711–22.

    Article  CAS  PubMed  Google Scholar 

  156. Martens LH, Zhang J, Barmada SJ, Zhou P, Kamiya S, Sun B, et al. Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury. J Clin Invest. 2012;122(11):3955–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  157. Wils H, Kleinberger G, Pereson S, Janssens J, Capell A, Van Dam D, et al. Cellular ageing, increased mortality and FTLD-TDP-associated neuropathology in progranulin knockout mice. J Pathol. 2012;228(1):67–76.

    CAS  PubMed  Google Scholar 

  158. Ahmed Z, Sheng H, Xu YF, Lin WL, Innes AE, Gass J, et al. Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am J Pathol. 2010;177(1):311–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  159. Ghoshal N, Dearborn JT, Wozniak DF, Cairns NJ. Core features of frontotemporal dementia recapitulated in progranulin knockout mice. Neurobiol Dis. 2012;45(1):395–408.

    Article  CAS  PubMed  Google Scholar 

  160. Yin F, Dumont M, Banerjee R, Ma Y, Li H, Lin MT, et al. Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. FASEB J. 2010;24(12):4639–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  161. Tanaka Y, Chambers JK, Matsuwaki T, Yamanouchi K, Nishihara M. Possible involvement of lysosomal dysfunction in pathological changes of the brain in aged progranulin-deficient mice. Acta Neuropathol Commun. 2014;2:78.

    Article  PubMed  PubMed Central  Google Scholar 

  162. Brouwers N, Nuytemans K, van der Zee J, Gijselinck I, Engelborghs S, Theuns J, et al. Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch Neurol. 2007;64(10):1436–46.

    Article  PubMed  Google Scholar 

  163. Cortini F, Fenoglio C, Guidi I, Venturelli E, Pomati S, Marcone A, et al. Novel exon 1 progranulin gene variant in Alzheimer’s disease. Eur J Neurol. 2008;15(10):1111–7.

    Article  CAS  PubMed  Google Scholar 

  164. Hosokawa M, Arai T, Masuda-Suzukake M, Kondo H, Matsuwaki T, Nishihara M, et al. Progranulin reduction is associated with increased tau phosphorylation in P301L tau transgenic mice. J Neuropathol Exp Neurol. 2015;74(2):158–65.

    Article  CAS  PubMed  Google Scholar 

  165. Filiano AJ, Martens LH, Young AH, Warmus BA, Zhou P, Diaz-Ramirez G, et al. Dissociation of frontotemporal dementia-related deficits and neuroinflammation in progranulin haploinsufficient mice. J Neurosci. 2013;33(12):5352–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  166. Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet. 2004;36(4):377–81.

    Article  CAS  PubMed  Google Scholar 

  167. Kimonis VE, Mehta SG, Fulchiero EC, Thomasova D, Pasquali M, Boycott K, et al. Clinical studies in familial VCP myopathy associated with Paget disease of bone and frontotemporal dementia. Am J Med Genet A. 2008;146A(6):745–57.

    Article  PubMed  PubMed Central  Google Scholar 

  168. Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010;68(5):857–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  169. Abramzon Y, Johnson JO, Scholz SW, Taylor JP, Brunetti M, Calvo A, et al. Valosin-containing protein (VCP) mutations in sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2012;33(9):2231 e1–6.

    Article  CAS  Google Scholar 

  170. Tang WK, Li D, Li CC, Esser L, Dai R, Guo L, et al. A novel ATP-dependent conformation in p97 N-D1 fragment revealed by crystal structures of disease-related mutants. EMBO J. 2010;29(13):2217–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  171. Rodriguez-Ortiz CJ, Hoshino H, Cheng D, Liu-Yescevitz L, Blurton-Jones M, Wolozin B, et al. Neuronal-specific overexpression of a mutant valosin-containing protein associated with IBMPFD promotes aberrant ubiquitin and TDP-43 accumulation and cognitive dysfunction in transgenic mice. Am J Pathol. 2013;183(2):504–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  172. Weihl CC, Miller SE, Hanson PI, Pestronk A. Transgenic expression of inclusion body myopathy associated mutant p97/VCP causes weakness and ubiquitinated protein inclusions in mice. Hum Mol Genet. 2007;16(8):919–28.

    Article  CAS  PubMed  Google Scholar 

  173. Custer SK, Neumann M, Lu H, Wright AC, Taylor JP. Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone. Hum Mol Genet. 2010;19(9):1741–55.

    Article  CAS  PubMed  Google Scholar 

  174. Badadani M, Nalbandian A, Watts GD, Vesa J, Kitazawa M, Su H, et al. VCP associated inclusion body myopathy and paget disease of bone knock-in mouse model exhibits tissue pathology typical of human disease. PLoS One. 2010;5(10):e13183.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  175. Nalbandian A, Llewellyn KJ, Badadani M, Yin HZ, Nguyen C, Katheria V, et al. A progressive translational mouse model of human valosin-containing protein disease: the VCP(R155H/+) mouse. Muscle Nerve. 2013;47(2):260–70.

    Article  CAS  PubMed  Google Scholar 

  176. Yin HZ, Nalbandian A, Hsu CI, Li S, Llewellyn KJ, Mozaffar T, et al. Slow development of ALS-like spinal cord pathology in mutant valosin-containing protein gene knock-in mice. Cell Death Dis. 2012;3:e374.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  177. Llewellyn KJ, Nalbandian A, Jung KM, Nguyen C, Avanesian A, Mozaffar T, et al. Lipid-enriched diet rescues lethality and slows down progression in a murine model of VCP-associated disease. Hum Mol Genet. 2014;23(5):1333–44.

    Article  CAS  PubMed  Google Scholar 

  178. Skibinski G, Parkinson NJ, Brown JM, Chakrabarti L, Lloyd SL, Hummerich H, et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet. 2005;37(8):806–8.

    Article  CAS  PubMed  Google Scholar 

  179. Ghazi-Noori S, Froud KE, Mizielinska S, Powell C, Smidak M, Fernandez de Marco M, et al. Progressive neuronal inclusion formation and axonal degeneration in CHMP2B mutant transgenic mice. Brain. 2012;135(Pt 3):819–32.

    Article  PubMed  Google Scholar 

  180. Vernay A, Therreau L, Blot B, Risson V, Dirrig-Grosch S, Waegaert R, et al. A transgenic mouse expressing CHMP2Bintron5 mutant in neurons develops histological and behavioural features of amyotrophic lateral sclerosis and frontotemporal dementia. Hum Mol Genet. 2016;25(15):3341–60.

    Article  CAS  PubMed  Google Scholar 

  181. Clayton EL, Mancuso R, Nielsen TT, Mizielinska S, Holmes H, Powell N, et al. Early microgliosis precedes neuronal loss and behavioural impairment in mice with a frontotemporal dementia-causing CHMP2B mutation. Hum Mol Genet. 2017;26(5):873–87.

    CAS  PubMed  PubMed Central  Google Scholar 

  182. Van Langenhove T, van der Zee J, Sleegers K, Engelborghs S, Vandenberghe R, Gijselinck I, et al. Genetic contribution of FUS to frontotemporal lobar degeneration. Neurology. 2010;74(5):366–71.

    Article  PubMed  Google Scholar 

  183. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323(5918):1205–8.

    Article  CAS  PubMed  Google Scholar 

  184. Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323(5918):1208–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  185. Dormann D, Rodde R, Edbauer D, Bentmann E, Fischer I, Hruscha A, et al. ALS-associated fused in sarcoma (FUS) mutations disrupt transportin-mediated nuclear import. EMBO J. 2010;29(16):2841–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  186. Mitchell JC, McGoldrick P, Vance C, Hortobagyi T, Sreedharan J, Rogelj B, et al. Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion. Acta Neuropathol. 2013;125(2):273–88.

    Article  CAS  PubMed  Google Scholar 

  187. Huang C, Zhou H, Tong J, Chen H, Liu YJ, Wang D, et al. FUS transgenic rats develop the phenotypes of amyotrophic lateral sclerosis and frontotemporal lobar degeneration. PLoS Genet. 2011;7(3):e1002011.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  188. Verbeeck C, Deng Q, Dejesus-Hernandez M, Taylor G, Ceballos-Diaz C, Kocerha J, et al. Expression of fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis. Mol Neurodegener. 2012;7:53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  189. Shelkovnikova TA, Peters OM, Deykin AV, Connor-Robson N, Robinson H, Ustyugov AA, et al. Fused in sarcoma (FUS) protein lacking nuclear localization signal (NLS) and major RNA binding motifs triggers proteinopathy and severe motor phenotype in transgenic mice. J Biol Chem. 2013;288(35):25266–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  190. Robinson HK, Deykin AV, Bronovitsky EV, Ovchinnikov RK, Ustyugov AA, Shelkovnikova TA, et al. Early lethality and neuronal proteinopathy in mice expressing cytoplasm-targeted FUS that lacks the RNA recognition motif. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):402–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  191. Shiihashi G, Ito D, Yagi T, Nihei Y, Ebine T, Suzuki N. Mislocated FUS is sufficient for gain-of-toxic-function amyotrophic lateral sclerosis phenotypes in mice. Brain. 2016;139(Pt 9):2380–94.

    Article  PubMed  Google Scholar 

  192. Qiu H, Lee S, Shang Y, Wang WY, Au KF, Kamiya S, et al. ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects. J Clin Invest. 2014;124(3):981–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  193. Sephton CF, Tang AA, Kulkarni A, West J, Brooks M, Stubblefield JJ, et al. Activity-dependent FUS dysregulation disrupts synaptic homeostasis. Proc Natl Acad Sci U S A. 2014;111(44):E4769–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  194. Sharma A, Lyashchenko AK, Lu L, Nasrabady SE, Elmaleh M, Mendelsohn M, et al. ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function. Nat Commun. 2016;7:10465.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  195. Scekic-Zahirovic J, Sendscheid O, El Oussini H, Jambeau M, Sun Y, Mersmann S, et al. Toxic gain of function from mutant FUS protein is crucial to trigger cell autonomous motor neuron loss. EMBO J. 2016;35(10):1077–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  196. Kino Y, Washizu C, Kurosawa M, Yamada M, Miyazaki H, Akagi T, et al. FUS/TLS deficiency causes behavioral and pathological abnormalities distinct from amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2015;3:24.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  197. Neumann M, Bentmann E, Dormann D, Jawaid A, DeJesus-Hernandez M, Ansorge O, et al. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain. 2011;134(Pt 9):2595–609.

    Article  PubMed  PubMed Central  Google Scholar 

  198. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  199. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  200. van der Zee J, Gijselinck I, Dillen L, Van Langenhove T, Theuns J, Engelborghs S, et al. A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum Mutat. 2013;34(2):363–73.

    Article  PubMed  CAS  Google Scholar 

  201. Chew J, Gendron TF, Prudencio M, Sasaguri H, Zhang YJ, Castanedes-Casey M, et al. Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science. 2015;348(6239):1151–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  202. Zhang YJ, Gendron TF, Grima JC, Sasaguri H, Jansen-West K, Xu YF, et al. C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nat Neurosci. 2016;19(5):668–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  203. O’Rourke JG, Bogdanik L, Muhammad AK, Gendron TF, Kim KJ, Austin A, et al. C9orf72 BAC transgenic mice display typical pathologic features of ALS/FTD. Neuron. 2015;88(5):892–901.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  204. Peters OM, Cabrera GT, Tran H, Gendron TF, McKeon JE, Metterville J, et al. Human C9ORF72 hexanucleotide expansion reproduces RNA foci and dipeptide repeat proteins but not neurodegeneration in BAC transgenic mice. Neuron. 2015;88(5):902–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  205. Liu Y, Pattamatta A, Zu T, Reid T, Bardhi O, Borchelt DR, et al. C9orf72 BAC mouse model with motor deficits and neurodegenerative features of ALS/FTD. Neuron. 2016;90(3):521–34.

    Article  CAS  PubMed  Google Scholar 

  206. Jiang J, Zhu Q, Gendron TF, Saberi S, McAlonis-Downes M, Seelman A, et al. Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuron. 2016;90(3):535–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  207. Esanov R, Cabrera GT, Andrade NS, Gendron TF, Brown RH Jr, Benatar M, et al. A C9ORF72 BAC mouse model recapitulates key epigenetic perturbations of ALS/FTD. Mol Neurodegener. 2017;12(1):46.

    Article  PubMed  PubMed Central  Google Scholar 

  208. Schludi MH, Becker L, Garrett L, Gendron TF, Zhou Q, Schreiber F, et al. Spinal poly-GA inclusions in a C9orf72 mouse model trigger motor deficits and inflammation without neuron loss. Acta Neuropathol. 2017;134(2):241–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  209. Koppers M, Blokhuis AM, Westeneng HJ, Terpstra ML, Zundel CA, Vieira de Sa R, et al. C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits. Ann Neurol. 2015;78(3):426–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  210. Atanasio A, Decman V, White D, Ramos M, Ikiz B, Lee HC, et al. C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice. Sci Rep. 2016;6:23204.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  211. Sudria-Lopez E, Koppers M, de Wit M, van der Meer C, Westeneng HJ, Zundel CA, et al. Full ablation of C9orf72 in mice causes immune system-related pathology and neoplastic events but no motor neuron defects. Acta Neuropathol. 2016;132(1):145–7.

    Article  PubMed  PubMed Central  Google Scholar 

  212. Burberry A, Suzuki N, Wang JY, Moccia R, Mordes DA, Stewart MH, et al. Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci Transl Med. 2016;8(347):347ra93.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  213. Ugolino J, Ji YJ, Conchina K, Chu J, Nirujogi RS, Pandey A, et al. Loss of C9orf72 enhances autophagic activity via deregulated mTOR and TFEB signaling. PLoS Genet. 2016;12(11):e1006443.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dementia Research Unit, School of Medical Sciences, The University of New South Wales, Sydney, NSW, Australia

    Lars M. Ittner, Wei S. Lee, Kristie Stefanoska & Prita R. Asih

  2. Transgenic Animal Unit, School of Medical Sciences, The University of New South Wales, Sydney, NSW, Australia

    Lars M. Ittner

  3. Neuroscience Research Australia, Sydney, NSW, Australia

    Lars M. Ittner

  4. Motor Neuron Disease Unit, School of Medical Sciences, The University of New South Wales, Sydney, NSW, Australia

    Wei S. Lee & Yazi D. Ke

Authors
  1. Lars M. Ittner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wei S. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kristie Stefanoska
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Prita R. Asih
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yazi D. Ke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lars M. Ittner .

Editor information

Editors and Affiliations

  1. University of Milan, Fondazione Ca’ Granda, IRCCS Ospedale Policlinico, Milan, Italy

    Daniela Galimberti

  2. University of Milan, Fondazione Ca’ Granda, IRCCS Ospedale Policlinico, Milan, Italy

    Elio Scarpini

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ittner, L.M., Lee, W.S., Stefanoska, K., Asih, P.R., Ke, Y.D. (2018). Alzheimer’s Disease and Frontotemporal Lobar Degeneration: Mouse Models. In: Galimberti, D., Scarpini, E. (eds) Neurodegenerative Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-72938-1_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-72938-1_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-72937-4

  • Online ISBN: 978-3-319-72938-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation